Literature DB >> 2562938

Therapeutic options in the management of chronic heart failure. Is there a drug of first choice?

M Packer1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2562938     DOI: 10.1161/01.cir.79.1.198

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


× No keyword cloud information.
  7 in total

Review 1.  Perindopril. A review of its pharmacokinetics and clinical pharmacology.

Authors:  R J Macfadyen; K R Lees; J L Reid
Journal:  Drugs       Date:  1990       Impact factor: 9.546

2.  Acute and long-term hemodynamic response to low-dose enoximone in refractory heart failure.

Authors:  K M McDonald; J J O'Sullivan; E W McWilliams; R C Conroy; B J Maurer
Journal:  Cardiovasc Drugs Ther       Date:  1989-12       Impact factor: 3.727

3.  Czech and Slovak spirapril intervention study (CASSIS). A randomized, placebo and active-controlled, double-blind multicentre trial in patients with congestive heart failure.

Authors:  J Widimský; H J Kremer; P Jerie; O Uhlír
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

4.  Effects of DPI 201-106, a novel cardiotonic agent, on hemodynamics, cardiac electrophysiology and arrhythmias induced by programmed ventricular stimulation in dogs with subacute myocardial infarction: a comparative study with dobutamine.

Authors:  T Ozaki; T Uematsu; S Nagashima; M Nishimoto; M Nakashima
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1991-10       Impact factor: 3.000

5.  The effect of treatment with angiotensin-converting enzyme inhibitors on survival of pediatric patients with dilated cardiomyopathy.

Authors:  A B Lewis; M Chabot
Journal:  Pediatr Cardiol       Date:  1993-01       Impact factor: 1.655

6.  Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure.

Authors:  R J MacFadyen; K R Lees; J L Reid
Journal:  Br Heart J       Date:  1993-04

7.  CUL4B contributes to cancer stemness by repressing tumor suppressor miR34a in colorectal cancer.

Authors:  Yanjun Li; Huili Hu; Yuxing Wang; Yujia Fan; Yang Yang; Beibei Guo; Xueyong Xie; Jiabei Lian; Baichun Jiang; Bo Han; Yanlei Wang; Changshun Shao; Yaoqin Gong
Journal:  Oncogenesis       Date:  2020-02-13       Impact factor: 7.485

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.